Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
First Greenland, now Iceland? Annexation joke by Trump ally gets frosty response in the Arctic nation. - 2Passenger Missing After Going Overboard Disney Cruise Ship
- 3Vote In favor of Your Favored Keeping an eye on
- 4SpaceX launches Starlink satellites from California on 160th Falcon 9 flight of the year (video)
- 5West Palm Beach Shorecrest, renderings of downtown waterfront condo
- REWE launches seventh Pick&Go test store in Hanover
- 'Euphoria' releases Season 3 trailer, premiere date: Watch Rue and Laurie finally face off
- German politician urges more face-to-face interaction in digital age
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- Truly amazing Palaces: Which Is Your Number one?
- Is an $85 apple pie worth it? Our Thanksgiving taste test says … maybe.
- Pick Your #1 Japanese Food
- Soldiers seize power in Guinea-Bissau and detain the president
- Antivirus Programming for Exhaustive Security
